Clinical Trial Detail

NCT ID NCT03661723
Title Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

glioblastoma multiforme

Therapies

Bevacizumab

Pembrolizumab

Bevacizumab + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.